| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | P2U; HP2U; P2U1; P2UR; P2Y2; P2RU1; P2Y2R |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human P2RY2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于P2RY2抗体的示例性参考文献(内容为模拟概括，建议通过学术数据库验证具体文献)：
1. **文献名称**: "Development of a Monoclonal Antibody Targeting P2RY2 for Inflammatory Disease Studies"
**作者**: Li, X. et al.
**摘要**: 研究团队开发了一种高特异性抗P2RY2的单克隆抗体，验证其在体外和小鼠模型中阻断ATP介导的炎症信号通路的能力，证明其可显著减少巨噬细胞炎症因子释放。
2. **文献名称**: "P2RY2 Receptor Expression in Cancer: A Novel Antibody-Based Detection Approach"
**作者**: Martinez, R. & Kumar, S.
**摘要**: 该文献报道了一种新型抗P2RY2抗体的制备，用于免疫组化检测多种癌症组织中P2RY2的过表达，并关联其与肿瘤迁移和患者预后的关系。
3. **文献名称**: "Role of P2RY2 in Airway Epithelial Function: Insights from Antibody-Mediated Inhibition"
**作者**: Chen, L. et al.
**摘要**: 通过使用特异性P2RY2抗体阻断受体活性，研究发现P2RY2调控气道黏液分泌和纤毛运动，为慢性阻塞性肺病(COPD)的治疗提供了潜在靶点。
4. **文献名称**: "Characterization of a Polyclonal P2RY2 Antibody for Mechanistic Studies in Renal Fibrosis"
**作者**: Gupta, P. et al.
**摘要**: 文献详细描述了多克隆抗体的开发及验证，证明其在肾纤维化模型中抑制P2RY2介导的成纤维细胞活化，减缓纤维化进展。
如需具体文献，建议通过PubMed或Google Scholar搜索关键词“P2RY2 antibody”或结合研究领域(如“inflammation”“cancer”)进一步筛选。
The P2RY2 antibody targets the P2Y2 receptor, a G protein-coupled receptor (GPCR) belonging to the purinergic receptor family. P2RY2 is activated by extracellular nucleotides like ATP and UTP, primarily coupling with Gq proteins to trigger intracellular calcium mobilization and downstream signaling pathways. This receptor is widely expressed in epithelial cells, immune cells, and certain neural tissues, playing critical roles in regulating physiological processes such as inflammation, epithelial fluid secretion, and bone metabolism. Dysregulation of P2RY2 signaling has been implicated in pathologies including cystic fibrosis, dry eye disease, and cancer.
Antibodies against P2RY2 are valuable tools for studying its expression, localization, and functional roles in vitro and in vivo. They enable detection of receptor levels in disease models, assessment of ligand-receptor interactions, and exploration of therapeutic targeting. Recent studies highlight P2RY2's potential as a biomarker or drug target, particularly in conditions involving aberrant purinergic signaling. For instance, monoclonal antibodies blocking P2RY2 activation are being explored to mitigate inflammation or tumor progression. However, challenges remain in developing high-specificity antibodies due to structural similarities among P2Y receptor subtypes. Ongoing research focuses on optimizing antibody affinity and selectivity, as well as elucidating context-dependent signaling mechanisms of P2RY2 in health and disease.
×
